In a report issued on December 17, Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report), with a price target of $150.00. The company's shares closed last Wednesday at $135.77. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Satsuma Pharmaceuticals, and Avadel Pharmaceuticals. Biohaven Pharmaceutical Holding Co has an analyst consensus of Strong Buy, with a price target consensus of $152.20, which is a 14.9% upside from current levels.
https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-biohaven-pharmaceutical-holding-co-bhvn-2?utm_source=advfn.com&utm_medium=referral
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Biohaven Pharmaceutical Charts.
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Biohaven Pharmaceutical Charts.